Buparlisib in breast cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Buparlisib (BKM 120) is an oral pan-PI3K inhibitor.
• It targets PI3K downstream signaling, leading to apoptosis in cancer cells.

Purpose of the Study:

• To evaluate the safety and efficacy of Buparlisib in cancer treatment.
• To assess the pharmacokinetic profile and adverse events associated with Buparlisib.

Main Methods:

• Phase I clinical trials were conducted.
• Pharmacokinetic properties, including absorption, bioavailability, and half-life, were assessed.
• Adverse events were systematically recorded.

Main Results:

• Buparlisib demonstrated rapid absorption, high bioavailability (>90%), good blood-brain barrier penetration, and a 40-hour half-life.
• Phase I trials indicated a good disease control rate with a tolerable toxicity profile at 100 mg.
• Common adverse events included rash, hyperglycemia, liver function derangements, and psychiatric events.

Conclusions:

• Buparlisib exhibits favorable pharmacokinetic properties and shows potential for disease control in early-phase trials.
• While generally well-tolerated, specific adverse events require monitoring.
• Further randomized trials are necessary to establish Buparlisib's role in breast cancer treatment and gain regulatory approval.